Biostage names Chinese health care executive to board
Courtesy | Biostage
Dr. Wei Zhang
Biostage has named another Chinese executive to its board of directors as it seeks to remake itself and explore new markets in different parts of the world.
Wei Zhang, a professor of innovation at Peking University, has been elected to the board, the Holliston biotech announced Friday. Zhang has led company-specific business strategy programs across the globe, including Novartis, Nestle, IBM, Johnson & Johnson, Roche and others.
Biostage hopes to treat conditions of the esophagus, bronchus and trachea by developing artificial organ implants intended to regenerate a patient’s own tissue. The company has recently indicated a shift to treating esophageal cancer patients with a particular focus on China and other Asian countries.
“I hope my experience leading and supporting strategy and innovation programs for companies around the world will help guide the company on future strategic decisions, including market expansion into China, which has half of the new esophageal cancer patients worldwide every year,” Zhang said.
Zhan’s career includes a five-year stint as a faculty member of management at China Europe International Business School, at which he was the founding director of the school’s Center for Healthcare Policy and Management.
WBJ Web Partners
Most Recent
Most Recent
0 Comments